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Abstract
Background: Psychotherapy for borderline personality disorder is often lengthy and resource-intensive. However,
the current length of outpatient treatments is arbitrary and based on trials that never tested if the treatment
intensity could be reduced. As a result, there is insufficient evidence to inform the decision between short-term and
long-term psychotherapy for borderline personality disorder. Mentalization-based therapy is one treatment option
for borderline personality disorder and consists traditionally of an 18-month treatment program.
Methods/design: This trial is an investigator-initiated single-center randomized clinical superiority trial of short-term
(20 weeks) compared to long-term (14 months) mentalization-based therapy for outpatients with subthreshold or
diagnosed borderline personality disorder. Participants will be recruited from the Outpatient Clinic for Personality
Disorders at Stolpegaard Psychotherapy Centre, Mental Health Services, Capital Region of Denmark. Participants will
be included if they meet a minimum of four DSM-V criteria for borderline personality disorder. Participants will be
assessed before randomization, and at 8, 16, and 24 months after randomization. The primary outcome is severity of
borderline symptomatology assessed with the Zanarini Rating Scale for borderline personality disorder. Secondary
outcomes include self-harm incidents, functional impairment (Work and Social Adjustment Scale, Global Assessment
of Functioning) and quality of life (Short-Form Health Survey 36). Severity of psychiatric symptoms (Symptom
Checklist 90-R) will be included as an exploratory outcome. Measures of personality functioning, attachment,
borderline symptoms, group alliance, and mentalization skills will be included to explore potential predictors and
mechanisms of change.
Discussion: This trial will provide evidence of the beneficial and harmful effects of short-term compared to long-
term mentalization-based therapy for outpatients with subthreshold or diagnosed borderline personality disorder.
Trial registration: ClinicalTrials.gov, NCT03677037. Registered on September 19, 2018.
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Background
Borderline personality disorder is a psychiatric condition
characterized by a pervasive pattern of symptoms such
as interpersonal conflicts, identity diffusion, impulsivity,
and emotional dysregulation [1]. According to epidemio-
logical studies, 1.6% of the general population suffer
from borderline personality disorder [2]. In clinical pop-
ulations, it is the most common personality disorder [2],
with a prevalence of between 9% and 22% of all psychi-
atric outpatients [3–5]. Borderline personality disorder is
associated with high levels of psychiatric comorbidity,
particularly depression, anxiety disorders, eating disor-
ders, substance abuse [6–8], and other personality disor-
ders [9]. Together, these findings emphasize the need for
the development of efficacious and cost-effective treat-
ments for this severe and highly prevalent disorder.
While pharmacological treatment may reduce some
borderline-related symptoms, there is still no convincing
evidence that it is suitable for treating all diagnostic cri-
teria [10]. Although further evidence is still warranted,
psychotherapy continues to be the primary treatment of
choice for borderline personality disorder [11]. During
the last 10–15 years, studies have established the efficacy
of different forms of intensive, specialized long-term
psychotherapy modalities. These have recently been
evaluated in a systematic review and meta-analysis ex-
ploring the efficacy of psychotherapies for borderline
personality disorder, in which it was concluded that dia-
lectical behavior therapy and psychodynamic therapies
(transference focused therapy and mentalization-based
therapy) significantly improved borderline-relevant out-
comes [12]. However, no single treatment modality has
been established as the primary treatment of choice.
Mentalization-based therapy (MBT) is a psycho-
dynamic therapy rooted in attachment and cognitive
theory [13], which was developed specifically for
treating borderline personality disorder [14]. Mentali-
zation refers to the capacity to understand one’s own
and others’ mental states. The theoretical assumption
is that patients with borderline personality disorder
are more vulnerable to lose this capacity when experi-
encing emotional distress. The MBT manual offers
therapeutic techniques to identify these shifts and to
bring the patient back into a mentalizing mode [14,
15]. The therapy program consists of four basic com-
ponents: (1) psycho-education, (2) case formulation,
(3) group therapy, and (4) individual therapy. All of
these aim to enhance the patient’s capacity to menta-
lize. Increasing mentalization skills is assumed to
minimize borderline-related symptoms such as emo-
tional dysregulation, impulsivity, and suicidal ideation.
However, information about the mechanisms that pro-
duce a change in MBT, or in psychotherapy in gen-
eral, is still limited [16, 17].
MBT for adult borderline personality disorder has
been tested in cohort studies [18, 19] and one random-
ized but uncontrolled trial [20]. Two forms of MBT have
been tested in randomized controlled trials: day hospital
MBT [21, 22] and intensive outpatient MBT [13], each
lasting a maximum of 18 months. For a systematic re-
view of the current evidence base of MBT for borderline
personality disorder, see Vogt and Norman [16].
Bateman and Fonagy [13] assessed the effects of inten-
sive outpatient MBT in a randomized clinical trial, in
which 134 participants with a confirmed borderline per-
sonality disorder diagnosis were randomized either to
18months of outpatient MBT, combining weekly group
and individual sessions with different therapists, or to
structured clinical management. In this trial, MBT was
superior to structured clinical management in terms of
its effects on suicide attempts, severe incidents of
self-harm, and on self-reported measures. Treatment ef-
fects were sustained at the 5-year follow-up [23]. Never-
theless, only 134 participants were randomized, which
questions whether the trial was powered to assess the
chosen outcomes, and only 41 were assessed after 5
years. Further, the trial investigators were also the devel-
opers of MBT. Thus, the small sample size and the sub-
stantial problems with incomplete outcome data,
especially at the long-term follow-up, are threats to the
validity of the study.
However, while intensive outpatient MBT currently has
empirical support as an 18-month program for borderline
personality disorder, evidence that this is the optimal
length of the intervention is not available. Consequently,
MBT is now offered for different lengths of time (both
shorter and longer) in outpatient settings around the
world [14]. Various other short-term psychotherapies for
borderline personality disorder have already been devel-
oped and tested in randomized clinical trials, e.g., emotion
regulation group therapy [24], systems training for emo-
tional predictability and problem-solving [25, 26], and
brief dialectical behavior therapy skills training [27]. How-
ever, all the trials have either compared a short-term ex-
perimental group to a short-term control group or tested
the short-term treatment as an adjunctive to treatment as
usual. Thus, these trials do not provide guidance on
evidence-based decisions regarding the optimal length of
treatment for borderline patients. In addition, no empir-
ical evidence is available to identify which subtypes of
patients would benefit from short-term treatment and
which would require more intensive treatment [28].
We performed a preliminary literature search
(PubMed and Cochrane Library) for trials comparing
different lengths of psychotherapy for borderline person-
ality disorder. No such trials were found. When we ex-
panded our search terms to all types of psychiatric
disorders, only few trials were identified [29, 30]. We are
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currently working on a protocol for a more compre-
hensive systematic review, including a full assessment
of risk of bias and a trial sequential analysis of
short-term compared with long-term psychotherapy
for all psychiatric disorders. The systematic review
will be submitted for publication before data collec-
tion is completed in this trial.
Methods/design
Objective
The primary objective of this trial will be to evaluate the
beneficial and harmful effects of short-term (20 weeks)
MBT compared with long-term (14months) MBT for
adult outpatients with subthreshold or diagnosed border-
line personality disorder. We will evaluate the treatments
on the primary outcome (borderline symptomatology),
secondary outcomes (self-harm incidents, quality of life,
and functional impairment, and exploratory outcomes
(psychiatric symptoms). Measures of personality function-
ing, attachment, borderline psychopathology, group
cohesion, and mentalization skills will be included as pre-
dictor and mediator variables.
Design
We have designed an investigator-initiated parallel-group
single-centre randomized clinical superiority trial of
short-term versus long-term MBT for outpatients with
subthreshold or diagnosed borderline personality disorder.
The Consolidated Standards of Reporting Trials (CON-
SORT) flow chart for the trial is shown in Fig. 1. [31, 32].
The Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) participant timeline is given
in Fig. 2, and the SPIRIT checklist is given in Add-
itional file 1 [33].
We will consider for participation all patients referred
to the trial site. Patients will be included in the trial, if
they comply with the eligibility criteria listed in Table 1.
There are inclusion and exclusion criteria as part of the
procedure for clinical intake at the trial site, and criteria
specific to this trial. For a detailed overview of typical
Fig. 1 Consolidated Standards of Reporting Trials (CONSORT) flow chart
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patient characteristics at the trial site, see Simonsen et
al. [34].
We will include participants with at least subthreshold
borderline personality disorder. According to the Diag-
nostic and Statistical Manual of Mental Disorders, 5th
edition (DSM-V) [1], the threshold for a full diagnosis is
five out of nine diagnostic criteria. However, there is in-
creasing evidence that even four confirmed diagnostic
criteria are not qualitatively different from diagnosed
borderline personality disorder in terms of impairment,
and that the diagnostic threshold should be more inclu-
sive than established by the DSM system to reflect the
dimensionality of the construct [35, 36]. For this reason,
previous trials have included participants with at least a
subthreshold diagnosis [24, 37], and we will do the same
in this trial.
Trial site and personnel
The trial site is the Outpatient Clinic for Personality Dis-
orders at Stolpegaard Psychotherapy Centre, Mental
Health Services, Capital Region of Denmark (from now
on referred to as “the clinic”). The clinic specializes in
MBT for borderline personality disorder. Patients are
referred from the Capital Region of Denmark via a cen-
tral visitation unit, where they are initially screened for
eligibility before referral to the clinic. Once referred to
the clinic, psychiatrists and attending physicians will per-
form the initial selection and screening of a participant
to the trial and collect informed consent. The principal
investigator, sponsor-investigator, or a trained research
assistant will then conduct the baseline assessments of
the participant. All post-baseline assessments will be car-
ried out by trial investigators who are blind to treatment
allocation.
Trial therapists provide therapy to both the short-term
and long-term treatment groups. Before commencing the
trial, all trial therapists at the clinic will have received
training in the short-term MBT program by trial investi-
gators and national and international MBT specialists.
The training covers relevant topics like case formulations,
termination of psychotherapy, and case-specific supervi-
sion. The training will continue throughout the trial
period. Therapist treatment fidelity will be rated by an in-
dependent certified rater. This will allow us to investigate
whether the delivered interventions adhere to the MBT
manual.
Fig. 2 Participant timeline for the Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT)
Table 1 Eligibility criteria
Criteria exclusive to the outpatient clinic Criteria exclusive to the trial
Inclusion
criteria
Aged 18–60
Personality disorder(s) considered to be the primary
diagnosis/diagnoses
A minimum of four confirmed DSM-V diagnostic criteria for
borderline personality disorder
Written informed consent
Exclusion
criteria
Possibility of a learning disability (IQ < 75)
A full diagnosis of schizotypal personality disorder or antisocial
personality disorder
Presence of a comorbid psychiatric disorder that requires specialist
treatment
Current (past 2 months) substance dependence including alcohol
Concurrent psychotherapeutic treatment outside the clinic
Unable to understand Danish
Lack of informed consent
DSM-V Diagnostic and Statistical Manual of Mental Disorders, 5th edition
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Randomization
Copenhagen Trial Unit, a Danish center for clinical
intervention research, will be responsible for the central
randomization. Trial investigators will call designated
staff at Copenhagen Trial Unit using a central telephone
to randomize eligible participants to either the experi-
mental group or the control group with a 1:1 allocation
according to a computer-generated allocation sequence
with permuted blocks of various sizes generated by
Copenhagen Trial Unit and unknown to the investiga-
tors, secretaries, and clinical staff at the trial site. This is
done to eliminate any predictability in the random se-
quence. The randomization is stratified by (1) sex and
(2) high/low scores on the primary outcome measure,
the Zanarini Rating Scale for Borderline Personality Dis-
order (ZAN-BPD) [38] at baseline.
Interventions
The short-term MBT program delivered in this trial is
overall similar to the existing long-term program, but
differs structurally in the following ways: (1) the
short-term program is lower in treatment intensity (both
duration and exposure), (2) the same therapists provide
both group and individual sessions in the short-term
program (conjoined psychotherapy), whereas the group
therapy and individual therapy are provided by different
therapists in the long-term program (combined psycho-
therapy), and (3) the short-term program is structured
in closed groups, in which all participants start and fin-
ish the program together, whereas the long-term pro-
gram is structured as slow-open groups, in which a new
participant can enter a group when another finishes.
Both interventions in this trial adhere to the treatment
guidelines provided by the National Institute for Health
and Care Excellence [39].
Experimental intervention
The short-term MBT program is designed as a 20-week
psychotherapy program consisting of five sessions of
introductory MBT (MBT-I) followed by 15 sessions of
group MBT (MBT-G) accompanied by conjoined indi-
vidual sessions every second week and two
psycho-educative meetings with participants and their
relatives. Seven to nine participants and two therapists
will be included in each short-term MBT group. The
groups are closed to enhance cohesion between group
participants. A total of 11 short-term MBT groups will
be included in this trial.
Originally, MBT-I was a 12-session introductory
psycho-educative program covering relevant topics like
personality disorders, attachment, and mentalization
[40]. The original manual has been modified for our
5-week intervention. A copy of our modified manual is
available upon request. After the completion of MBT-I,
the same group of participants will move on to MBT-G,
which consists of 15 sessions of mentalization-based
psychotherapy in groups, as manualized by Bateman and
Fonagy [14]. In our short-term MBT program, group
sessions will be accompanied by individual psychother-
apy every second week with one of the two group thera-
pists. As part of the individual therapy, a case
formulation will be prepared and subsequently shared by
the participants in the group. The overall purpose of the
individual sessions is for the therapist and participant to
develop a consensus of the participant’s main difficulties
and to establish psychotherapeutic focus points in the
group therapy. Furthermore, participants and relatives
will be invited to two psycho-educative meetings hosted
by the therapists at the beginning of the treatment pro-
gram to enhance the mentalization work at home. The
participants in the short-term MBT program will fur-
thermore be offered three individual follow-up sessions
after the end of treatment.
Control intervention
Long-term MBT is organized as a 14-month program
and has been implemented at the clinic for the past 7
years. All participants randomized to long-term MBT
will initially enter a 6-week MBT-I program manualized
by Karterud and Bateman [40] and modified for our
6-week intervention in collaboration with the authors.
New MBT-I groups commence every time new partici-
pants are recruited and randomized to long-term MBT.
A maximum of 12 participants can enter an MBT-I
group. When MBT-I finishes, participants will be allo-
cated to one of eight slow-open MBT treatment groups.
MBT-G is then organized as 12 months of weekly group
therapy sessions, also manualized by Bateman and
Fonagy [14]. In the long-term MBT program, group ses-
sions will be accompanied by combined individual MBT
sessions every 2 weeks throughout the program. As part
of the individual therapy, a case formulation will be de-
veloped and subsequently shared with the group by the
participant. Furthermore, participants and relatives will
also be invited to two psycho-educative meetings hosted
by the therapists to enhance the mentalization work at
home. When a participant drops out or completes
MBT-G, a new participant can start in the group. This
procedure continues until the target sample size has
been randomized to the long-term MBT program. The
participants in the long-term MBT program will also be
offered three individual follow-up sessions after the end
of treatment.
Concomitant interventions
Participants who are receiving psychotropic treatment
will be allowed to continue their medical treatment
while participating in the trial. The medical protocol will
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follow national as well as international medical recom-
mendations for the treatment of borderline personality
disorder and comorbid disorders [39, 41]. Psychiatrists
or attending physicians at the clinic will assess the need
for additional psychotropic treatment and are asked to
adhere to the guidelines. All participants, regardless of
treatment condition, will be asked about their current
medication by trial personnel during trial interviews to
allow us to measure any potential differences in the use
of psychotropic medication between the groups.
Baseline assessment at trial intake
Baseline assessments will be carried out prior to
randomization by the principal investigator, the
sponsor-investigator, and a trained research assistant, all
of whom are also clinical psychologists. General psycho-
pathology will be assessed with the Mini International
Neuropsychiatric Interview (MINI) [42]. Personality disor-
ders will be assessed with the Structured Clinical Interview
for DSM-V Personality Disorders (SCID-5-PD), formerly
known as SCID-II [43]. The SCID-5-PD is considered the
gold standard for clinician-administered semi-structured
interviews designed to assess personality disorders accord-
ing to DSM-V criteria [44].
Outcomes
Primary outcome
The primary outcome is the severity of borderline symp-
tomatology assessed with the ZAN-BPD [38], which is a
clinician-administered scale for the assessment of change
in borderline psychopathology over time. Each of the
nine borderline personality disorder criteria are rated on
a 0 to 4 anchored scale reflecting the severity of symp-
toms. The rating is intended to reflect both the fre-
quency and the severity of borderline psychopathology.
The interview provides a total score of borderline psy-
chopathology ranging from 0 to 36. ZAN-BPD will be
assessed by investigators blind to treatment allocation at
baseline, and at the 8-, 16-, and 24-month follow-ups.
We will video-record interviews to allow an assessment
of inter-rater reliability based on the intraclass correl-
ation coefficient. The results will be evaluated using the
guidelines provided by Cicchetti [45].
Secondary outcomes
Functional impairment will be assessed with the Work
and Social Adjustment Scale (WSAS) [46, 47]. This
self-report scale will be assessed at baseline, and at
the 8-, 16-, and 24-month follow-ups. Quality of life
will be assessed with the Short-Form Health Survey
(SF-36) [48], which consists of a mental and a phys-
ical component. We will use the mental component
as a secondary outcome and the physical component
as an exploratory outcome. This self-report scale will
be given at baseline, and at the 8-, 16-, and 24-month
follow-ups. Global functioning will be measured with
the Global Assessment of Functioning (GAF) split
version [49]. GAF will be assessed by investigators
blind to treatment allocation at baseline, and at the
8-, 16-, and 24-month follow-ups. Inter-rater reliabil-
ity will be calculated using the previously mentioned
guidelines. Severe self-harm (dichotomous data) will
be measured as the proportion of participants with
severe self-harm defined as deliberate acts of
self-harm resulting in visible tissue damage. Self-harm
will be assessed by investigators blind to treatment al-
location using the Suicide and Self-harm Inventory
(SSHI) (citation) at baseline, and at the 8-, 16-, and
24-month follow-ups.
Exploratory outcomes
Symptom distress will be measured with the Global Se-
verity Index (GSI) of the Symptom Checklist 90-R
(SCL-90-R) [50]. SCL-90-R will be given at baseline, and
at the 8-, 16-, and 24-month follow-ups.
Potential predictors and mediators
Questionnaires are given at baseline and every fourth
week throughout the intervention period for both
intervention groups to allow us to explore predictors
and mechanisms of change. In a separate statistical
analysis plan, which will be submitted for publication
before data collection is completed in this trial, we
will describe how these exploratory analyses will be
performed. The following predictors and mediators
will be investigated.
Personality functioning will be assessed with the Levels
of Personality Functioning Scale, Brief Form (LPFS-BF)
[51], which is a newly developed brief 12-item
self-report questionnaire assessing levels of personality
functioning according to the DSM-V alternative model
for personality disorders. Attachment will be assessed
with the brief self-report Relationship Questionnaire
(RQ), which gives continuous and categorical ratings of
the four attachment styles [52]. Borderline symptomatol-
ogy will be assessed using the Zanarini Rating Scale for
Borderline Personality Disorder, Self-Report Version
(ZAN-BPD-SRV) [53]. Group alliance will be assessed
using the 12-item version of the Group Questionnaire
(GQ) [54], which is a brief self-report measure of the
three core components of group alliance: alliance to the
other participants, alliance to the therapists, and group
cohesion as a whole. Mentalization skills will be assessed
with the 15-item Mentalization Questionnaire (MZQ)
[55].
For an overview of all measures and the corresponding
time of assessment, see Table 2.
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Blinding
Trial participants and therapists will not be blind to
treatment allocation. This is due to the difficulties of
implementing an efficient blinding procedure in psycho-
therapy trials. Baseline assessments will be done before
allocation of participants, and the outcome assessments
will be performed by blinded assessors. Participants will
be instructed to withhold information of their allocation
group when assessed. The statistical analyses will be
conducted by blinded external statisticians from
Copenhagen Trial Unit with the intervention groups
coded as A and B. The steering committee will write
and agree on two abstracts while the blinding is intact;
one assuming the experimental intervention group is A
and the control intervention group is B, and the other
assuming the opposite. After this, the randomization
code will be broken [56, 57].
Participant discontinuation and withdrawal
Participants can withdraw from the trial at any time
without giving a reason and without consequences for
future treatment at the clinic. To secure data for the
trial, a trial investigator will contact the participant and
ask what aspects of the trial the participant wishes to
withdraw from: (1) the trial intervention or control
group, (2) the assessment interviews, or (3) use of
already collected data in analyses. If the participant spe-
cifies that they wish to withdraw fully and thereby with-
draw from all the points above, their data will be deleted
and not used in any analysis. The trial investigator will
encourage the participant to continue attending the
follow-up assessments.
Data management
The data in this trial will be collected using electronic
case report forms developed in the data collection sys-
tem REDCap. The system has been approved by the
Danish Data Protection Agency and fulfills the require-
ments for data security. Data from the interviews will be
entered directly into REDCap on a tablet, and all
self-report measures will be collected from REDCap. For
a detailed overview of outcome measures and data col-
lection time points, see Table 2. The only source data
are participants’ signed consent forms.
Student assistants employed in the research depart-
ment but not otherwise involved in the trial will make
sure that all self-report measures are sent to participants
at the right times, and that the data are complete for all
participants enrolled in the trial. The REDCap database
has an integrated audit trail to document any access to
and changes of the data. The validated data will be
exported to SAS for further statistical analyses by statis-
ticians from Copenhagen Trial Unit.
Statistical plan and data analysis
Sample size
The sample size was determined by the predicted change
in the primary outcome measure, ZAN-BPD. A
3.5-point superiority margin is considered to be the min-
imal important difference. Consistent with previous tri-
als that have used ZAN-BPD as an outcome measure for
a patient group like ours [24, 58], we expect a standard
deviation of 8. With power set at 80% and alpha set at
5% two-tailed, a sample size of 83 participants is needed
in each treatment group, corresponding to a total of 166
participants.
Statistical methods
All continuous outcomes will be assessed using linear re-
gression and dichotomous outcomes will be analyzed
using logistic regression. The analyses will be based on an
intention-to-treat population and will primarily be ad-
justed for the baseline value of the outcome of interest
and the stratification variables used in the randomization.
We will secondly adjust all analyses for the following de-
sign variables: age (18–30 and 30–60) and functional im-
pairment as assessed with the overall baseline GAF score
(0–48 and 49–100) [34].
We will use a five-step procedure [59] to assess if the
thresholds for statistical and clinical significance are
crossed and we will handle missing data according to
the procedure suggested by Jakobsen et al. [60]. A de-
tailed statistical analysis plan will be published before
the analyses commence, in which we will provide a de-
tailed description of all primary, secondary, and explora-
tory analyses. All analyses will be performed blinded
with the two intervention groups concealed as A and B.
Table 2 Assessments administered at baseline and each follow-up point throughout the trial
Assessment points Self-report measures Expert ratings
Baseline LPFS-BF, RQ, SF-36, WSAS, SCL-90-R, MZQ MINI, SCID-5-PD, ZAN-BPD, GAF, SSHI
Every 4 weeks GQ, MZQ, ZAN-BPD-SRV –
Follow-ups at 8, 16, and 24months SF-36, WSAS, SCL-90-R, MZQ ZAN-BPD, SSHI, GAF
GAF Global Assessment of Functioning, GQ Group Questionnaire, LPFS-BF Level of Personality Functioning Scale, Brief Form, MINI Mini International
Neuropsychiatric Interview, MZQ Mentalization Questionnaire, RQ Relationship Questionnaire, SCID-5-PD Structured Clinical Interview for DSM-V Personality
Disorders, SCL-90-R Symptom Checklist 90-R, SF-36 Short-Form Health Survey 36, SSHI Suicide and Self-Harm Inventory, WSAS Work and Social Adjustment Scale,
ZAN-BPD Zanarini Rating Scale for Borderline Personality Disorder, ZAN-BPD-SRV Zanarini Rating Scale for Borderline Personality Disorder, Self-Report Version
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Interim analyses
An external data safety monitoring committee will per-
form interim analyses when 50% of the data have been
collected according to the good clinical practice guide-
lines of the International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human
Use [61]. It will decide whether the trial should stop or
carry on. Early stopping criteria will follow the recom-
mendations of Jakobsen et al. [59].
Discussion
This trial will provide evidence of the beneficial and harmful
effects of short-term compared to long-term MBT for out-
patients with subthreshold or diagnosed borderline person-
ality disorder. To the best of our knowledge, short-term
MBT has never been tested before. Gaining more informa-
tion on how different lengths of treatment work for specific
subtypes of patients may help to minimize the potential
burden from long-term psychotherapy for some, while at
the same time it may identify subtypes of patients for whom
short-term psychotherapy is contraindicated. This know-
ledge may enhance the cost-effectiveness of treatment op-
tions for borderline personality disorder. Further, this trial
may provide information on the potential predictors and
mediators of treatment response.
The present trial has several strengths. First, it has a
high degree of external validity because of the relatively
inclusive eligibility criteria. Second, the methodology is
based on CONSORT, and was predefined and described
in detail before randomization began, including, e.g.,
blinding of all possible parties and implementation of a
central randomization system both for generating an al-
location sequence and for concealing allocation. Third,
the implementation of systematic treatment fidelity rat-
ings allows us to investigate treatment fidelity in both
groups.
Our trial also has limitations. First, no systematic review
of the effects of short-term compared to long-term psycho-
therapy for psychiatric disorders is currently available. As
mentioned earlier, we are currently performing such a re-
view. Second, the long-term MBT intervention, which is 14
months of treatment in this trial, diverges in intensity (both
duration and exposure) from the original 18-month pro-
gram [13]. This is due to the fixed length of the treatment
packages, which have been implemented in the Danish
mental health care system. Third, we cannot account for
any potential confounding variables because of the struc-
tural differences between the groups: the short-term MBT
program is closed and conjoined, whereas the long-term
program is slow-open and combined.
Dissemination policy
The Danish population will be informed of the trial as
well as its final results through national media. The
results of the trial will be presented at all outpatient
clinics treating borderline personality disorder in the
Mental Health Services, Capital Region of Denmark, by
the principal investigator or sponsor-investigator. The
final and interim results will be presented at national
and international conferences. Further, associations for
patients and relatives will be informed about the results
of the trial and its future implications. The trial results
will be written up by the steering committee and will be
published in international peer-reviewed journals. The
government of Denmark will be informed of the results
before a press release is issued but will have no influence
on the reporting of results.
Trial status
The current protocol is version 1, dated 9 October 2018.
The first participant was enrolled on 24 September 2018.
Recruitment is expected to be completed by September 1,
2020
Additional file
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